154 related articles for article (PubMed ID: 35027319)
21. Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses.
Le LP; Dias-Santagata D; Pawlak AC; Cosper AK; Nguyen AT; Selim MA; Deng A; Horick NK; Iafrate AJ; Mihm MC; Hoang MP
PLoS One; 2012; 7(10):e47290. PubMed ID: 23056620
[TBL] [Abstract][Full Text] [Related]
22. Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior.
Schwartz CJ; Ruiz J; Bean GR; Sirohi D; Joseph NM; Hosfield EM; Jacobs TW; Mukhtar RA; Chen YY; Krings G
Mod Pathol; 2023 May; 36(5):100125. PubMed ID: 36870308
[TBL] [Abstract][Full Text] [Related]
23. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.
Naderi A; Chia KM; Liu J
Breast Cancer Res; 2011 Apr; 13(2):R36. PubMed ID: 21457548
[TBL] [Abstract][Full Text] [Related]
24. Androgen and estrogen receptor mRNA status in apocrine carcinomas.
Bratthauer GL; Lininger RA; Man YG; Tavassoli FA
Diagn Mol Pathol; 2002 Jun; 11(2):113-8. PubMed ID: 12045715
[TBL] [Abstract][Full Text] [Related]
25. Bilateral apocrine carcinoma of the breast. Molecular and immunocytochemical evidence for two independent primary tumours.
Schmitt FC; Soares R; Seruca R
Virchows Arch; 1998 Dec; 433(6):505-9. PubMed ID: 9870682
[TBL] [Abstract][Full Text] [Related]
26. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.
Niemeier LA; Dabbs DJ; Beriwal S; Striebel JM; Bhargava R
Mod Pathol; 2010 Feb; 23(2):205-12. PubMed ID: 19898421
[TBL] [Abstract][Full Text] [Related]
27. An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity.
Moore NL; Buchanan G; Harris JM; Selth LA; Bianco-Miotto T; Hanson AR; Birrell SN; Butler LM; Hickey TE; Tilley WD
Endocr Relat Cancer; 2012 Aug; 19(4):599-613. PubMed ID: 22719059
[TBL] [Abstract][Full Text] [Related]
28. ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast.
Vranic S; Gatalica Z; Deng H; Frkovic-Grazio S; Lee LM; Gurjeva O; Wang ZY
J Clin Pathol; 2011 Jan; 64(1):54-7. PubMed ID: 21045236
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological characteristics of the SOX10+ subset of HER2+ breast cancer.
Weisman P; Yu Q; Xu J
Ann Diagn Pathol; 2023 Apr; 63():152087. PubMed ID: 36669230
[TBL] [Abstract][Full Text] [Related]
30. α-Methylacyl-CoA racemase: a useful immunohistochemical marker of breast carcinoma with apocrine differentiation.
Nakamura H; Kukita Y; Kunimasa K; Kittaka N; Kusama H; Nakayama T; Tamaki Y; Sugiura R; Yasuda H; Hashimoto M; Yamamoto T; Imamura F; Nakatsuka SI
Hum Pathol; 2021 Oct; 116():39-48. PubMed ID: 34314764
[TBL] [Abstract][Full Text] [Related]
31. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
[TBL] [Abstract][Full Text] [Related]
32. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
[TBL] [Abstract][Full Text] [Related]
33. IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast.
Vranic S; Gurjeva O; Frkovic-Grazio S; Palazzo J; Tawfik O; Gatalica Z
Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):413-6. PubMed ID: 21436679
[TBL] [Abstract][Full Text] [Related]
34. Hsa-mir-3163 and CCNB1 may be potential biomarkers and therapeutic targets for androgen receptor positive triple-negative breast cancer.
Qiu P; Guo Q; Yao Q; Chen J; Lin J
PLoS One; 2021; 16(11):e0254283. PubMed ID: 34797837
[TBL] [Abstract][Full Text] [Related]
35. Molecular characterization of apocrine salivary duct carcinoma.
Chiosea SI; Williams L; Griffith CC; Thompson LD; Weinreb I; Bauman JE; Luvison A; Roy S; Seethala RR; Nikiforova MN
Am J Surg Pathol; 2015 Jun; 39(6):744-52. PubMed ID: 25723113
[TBL] [Abstract][Full Text] [Related]
36. The expression of GHRH and its receptors in breast carcinomas with apocrine differentiation-further evidence of the presence of a GHRH pathway in these tumors.
Kővári B; Vranic S; Marchio C; Sapino A; Cserni G
Hum Pathol; 2017 Jun; 64():164-170. PubMed ID: 28438614
[TBL] [Abstract][Full Text] [Related]
37. Triple Negative Apocrine Carcinomas as a Distinct Subtype of Triple Negative Breast Cancer: A Case-control Study.
Meattini I; Pezzulla D; Saieva C; Bernini M; Orzalesi L; Sanchez LJ; Desideri I; Francolini G; Bonomo P; Greto D; Loi M; Mangoni M; Bruni A; Nori J; Vezzosi V; Bianchi S; Livi L
Clin Breast Cancer; 2018 Oct; 18(5):e773-e780. PubMed ID: 29573977
[TBL] [Abstract][Full Text] [Related]
38. Identification of molecular apocrine breast tumours by microarray analysis.
Farmer P; Bonnefoi H; Becette V; Tubiana-Hulin M; Fumoleau P; Larsimont D; Macgrogan G; Bergh J; Cameron D; Goldstein D; Duss S; Nicoulaz AL; Brisken C; Fiche M; Delorenzi M; Iggo R
Oncogene; 2005 Jul; 24(29):4660-71. PubMed ID: 15897907
[TBL] [Abstract][Full Text] [Related]
39. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
40. FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast.
Gromov P; Espinoza JA; Talman ML; Honma N; Kroman N; Timmermans Wielenga V; Moreira JM; Gromova I
PLoS One; 2014; 9(11):e112024. PubMed ID: 25389781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
